O-Acetyl-GD2 as a Therapeutic Target for Breast Cancer Stem Cells.

ABSTRACT:

Synopsis

A sugar-lipid molecule called OAcGD2 is a novel marker for breast cancer stem cells. Treatment with anti-OAcGD2 mAb8B6 may have superior anticancer efficacy by targeting cancer stem cells, thereby reducing metastasis and recurrence of cancer.

Background

Cancer stem cells (CSCs) that drive tumor progression and disease recurrence are rare subsets of tumor cells. CSCs are relatively resistant to conventional chemotherapy and radiotherapy. Eradication of CSCs is thus essential to achieve durable responses. GD2 was reported to be a CSC marker in human triple-negative breast cancer, and anti-GD2 immunotherapy showed reduced tumor growth in cell lines. Using a specific anti-OAcGD2 antibody, mAb8D6, we set out to determine whether OAcGD2⁺ cells exhibit stem cell

SUBMITTER: Cheng JY 

PROVIDER: S-EPMC8761789 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature